Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death

  • Huang W
  • Li C
  • Lin C
  • et al.
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND Clinical studies have obtained inconsistent results of statin use on cancer outcomes. This study investigated the association between statin use and lung cancer mortality. RESULTS The use of statin decreased mortality (hazard ratio = 0.91; 95% confidence interval: 0.86-0.96; P < .01). The patients with a high cumulative defined daily dose of statin use before lung cancer diagnosis exhibited a low risk of mortality. MATERIALS AND METHODS We conducted a population-based case-control study of patients with dyslipidemia. Among them, 6270 had used statins for at least 3 months before lung cancer diagnosis, and 6270 had never used statins. CONCLUSIONS We found that statin use can reduce lung cancer mortality. A further prospective study is necessary to confirm these findings.

Cite

CITATION STYLE

APA

Huang, W.-Y., Li, C.-H., Lin, C.-L., & Liang, J.-A. (2016). Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death. Oncotarget, 7(27). https://doi.org/10.18632/oncotarget.9906

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free